Armata Pharmaceuticals, Inc. (ARMP)
- Previous Close
2.5308 - Open
2.4900 - Bid 2.2500 x 1000
- Ask 3.3300 x 1200
- Day's Range
2.4900 - 2.8000 - 52 Week Range
1.0700 - 5.2600 - Volume
9,508 - Avg. Volume
15,661 - Market Cap (intraday)
99.765M - Beta (5Y Monthly) 0.70
- PE Ratio (TTM)
-- - EPS (TTM)
-1.9100 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.
www.armatapharma.comRecent News: ARMP
Performance Overview: ARMP
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARMP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARMP
Valuation Measures
Market Cap
99.76M
Enterprise Value
206.61M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.06
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.16
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.32%
Return on Equity (ttm)
-3,439.35%
Revenue (ttm)
4.53M
Net Income Avi to Common (ttm)
-69.05M
Diluted EPS (ttm)
-1.9100
Balance Sheet and Cash Flow
Total Cash (mrq)
13.52M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-27.75M